TITLE

Radiation oncology

PUB. DATE
August 1997
SOURCE
Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS90
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
Presents an abstract of the research manuscript `Cytotoxic effects of Ad5CMV-p53 expression in two human nasopharyngeal carcinoma cell lines,' by F.-F. Liu et al.
ACCESSION #
9708176140

 

Related Articles

  • Radiation oncology.  // Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS90 

    Presents an abstract of the research manuscript `The effects of combining ionizing radiation and adenovirus-mediated p53 gene transfer in human nasopharyngeal carcinoma cell lines,' by F.-F. Liu et al.

  • P53 Overexpression and Steroid Hormone Receptor Status in Endometrial Carcinoma. Fernando, Sujatha S.E. // International Journal of Surgical Pathology;Jul2000, Vol. 8 Issue 3, p213 

    Examines the overexpression of p53 protein in primary endometrial carcinomas. Association between nuclear p53 protein immunoreactivity and pathological features; Analysis of the immunohistochemical expression of estrogen receptors, progesterone receptors and pS2 protein; Correlation between...

  • p53 expression in low grade dysplasia in Barrett’s esophagus: correlation with interobserver agreement and disease progression Skacel, Marek; Petras, Robert E.; Rybicki, Lisa A.; Gramlich, Terry L.; Richter, Joel E.; Falk, Gary W.; Goldblum, John R. // American Journal of Gastroenterology;Oct2002, Vol. 97 Issue 10, p2508 

    OBJECTIVES:The frequency of progression from low grade dysplasia (LGD) to high grade dysplasia/carcinoma (HGD/CA) in Barrett’s esophagus (BE) varies among studies. Current assessment is made more difficult because of pathologists’ interobserver variability in diagnosing LGD. We...

  • Response of Ewing tumor cells to forced and activated p53 expression. Kovar, Heinrich; Pospisilova, Sarka; Jug, Gunhild; Printz, Dieter; Gadner, Helmut // Oncogene;5/22/2003, Vol. 22 Issue 21, p3193 

    The EWS-FLI1 transcription factor is consistently expressed in 85% of Ewing tumors (EFT). In heterologous cells, EWS-FLI1 induces p53-dependent cell cycle arrest or apoptosis. It has been speculated that the p53 tumor suppressor pathway may be generally compromised in EFT despite only rare p53...

  • Synergistic and opposing regulation of the stress-responsive gene IEX-1 by p53, c-Myc, and multiple NF-κB/rel complexes. Huang, Yan-Hong; Wu, Jim Yujin; Zhang, Yujin; Wu, Mei X. // Oncogene;10/3/2002, Vol. 21 Issue 44, p6819 

    Provides information on a study that examined how transcription factors Nf-κB/rel proteins, p53 and c-Myc coordinarily control immediate early response gene X-1 expression. Results and discussion; Materials and methods used.

  • Nucleophosmin regulates the stability and transcriptional activity of p53. Colombo, Emanuela; Marine, Jean-Christophe; Danovi, Davide; Falini, Brunangelo; Pelicci, Pier Giuseppe // Nature Cell Biology;Jul2002, Vol. 4 Issue 7, p529 

    Nucleophosmin (NPM) is a ubiquitously expressed nucleolar phosphoprotein that continuously shuttles between the nucleus and cytoplasm. It has been proposed to function in ribosomal protein assembly and transport, and also as a molecular chaperone that prevents proteins from aggregating in the...

  • Overexpression of p53 tumor suppressor gene in pterygia. Weinstein, O.; Rosenthal, G.; Zirkin, H.; Monos, T.; Lifshitz, T.; Argov, S. // Eye;Sep2002, Vol. 16 Issue 5, p619 

    Assesses p53 gene expression in pterygia with and without recurrence. Identification of prognostic factor for recurrence; Cell proliferation; Gene localization; Prevalence of p53 abnormal expression.

  • Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models. Wen, Shu Fen; Xie, Lei; McDonald, Matthew; DiGiacomo, Ruth; Chang, Alice; Gurnani, Maya; Shi, Bin; Liu, Suxing; Indelicato, Stephen R; Hutchins, Beth; Nielsen, Loretta L // Cancer Gene Therapy;Nov2000, Vol. 7 Issue 11, p1469 

    SCH58500 (ACN53) is a replication-deficient, type 5 adenovirus (Ad) expressing human wild-type p53 tumor suppressor. It is currently undergoing clinical trials as a cancer therapeutic. Many SCH58500 clinical trials incorporate an arm comparing traditional chemotherapy against chemotherapy...

  • MAYO CLINIC: PROCEEDINGS. Genden, Eric M.; Aguirre-Ghiso, Julio A. // Mayo Clinic Proceedings;Mar2012, Vol. 87 Issue 3, p211 

    An introduction to the journal is presented in which the editor discusses various articles within the issue on topics including oropharyngeal cancer, expression of p53 gene pathway, and genetic profiling of oropharyngealsquamouscell carcinoma (OPSCC) tumors.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics